Despite diversity enrollment goals, clinical trials funded by the National Institutes of Health (NIH) often enroll fewer patients among underrepresented racial groups; nicotine alternatives used in vapes may be more potent and addictive than nicotine itself; telehealth company Ro built a drug supply tracker to help patients find available doses of GLP-1 drugs.
Despite diversity enrollment goals, a recent study by the HHS Office of Inspector General found that clinical trials funded by the National Institutes of Health (NIH) often enroll fewer patients among underrepresented racial and gender groups, according to Stat. Researchers who apply for NIH funding must explain how they plan to enroll patients who represent the population affected by the condition for which treatments are being studied. The “inclusion plans” must include a numerical breakdown of targeted participant demographics by gender, ethnicity, and race. Most trials analyzed missed planned enrollment targets; some missed by a little, while others missed by a lot. They commonly recruited fewer female, Asian, Black, Native American and Alaska Native participants. Consequently, the FDA is expected to soon provide guidance on diversifying clinical trials.
The FDA found that nicotine alternatives used in vapes, like 6-methyl nicotine, may be more potent and addictive than nicotine itself, according to Reuters. These synthetic substances with similar chemical structures to nicotine are not subject to US tobacco and vaping regulations, which are used to control traditional nicotine. This means manufacturers can sell vapes containing these synthetic nicotine substances in the US without seeking FDA authorization. Altria, the maker of Marlboro cigarettes in the US, recently wrote a letter to the FDA, highlighting the emerging use of 6-methyl nicotine in vapes and other smoking alternatives. It urged the FDA to evaluate the compounds and establish the same authority over them as it has over nicotine; it also noted that the growth of these chemicals “could present unknown risks to US consumers and undermine FDA’s authority” if left unchecked.
Telehealth company Ro built a drug supply tracker to help patients find available doses of GLP-1 drugs, according to Axios. The demand for these drugs has led to shortages, resulting in patients with prescriptions having trouble finding the treatments when needed. Ro’s tracker relies on the company’s supply data and user-generated reports to provide real-time availability of drugs like Zepbound and Ozempic; patients can sign up for email alerts for when drugs are in stock at local pharmacies. An AI health assistant app Together by Renee launched its similar Find My Meds feature earlier this month, which automatically calls and transfers GLP-1 prescriptions to nearby pharmacies where the drug is available for refills.
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen